| Autor: |
Yung, Margaret, Narayanaswami, Pushpa, Pesa, Jacqueline, Choudhry, Zia, Jackson, Louis, Deering, Kathleen L., Sebaaly, Jamie, Richardson, Jordan, Feldman, Josh, Peters, Wesley, Taylor, Melina, Foss, Allison, West, Bruce, Shea, Lisa, Geonnotti, Gabrielle, Govindarajan, Raghav |
| Předmět: |
|
| Zdroj: |
Health Science Reports; Sep2024, Vol. 7 Issue 9, p1-12, 12p |
| Abstrakt: |
Background and Aims: Due to the high symptom and treatment burden in myasthenia gravis (MG), understanding patient and care partner perspectives and preferences is crucial. Methods: This study used voice analysis and virtual focus groups to understand patient and care partner experiences with MG‐related symptoms, treatments, and preferences. The voice analysis via social media listening used artificial intelligence‐powered tools to gather and structure public digital conversations on MG. Focus groups included people living with MG and care partners who completed a questionnaire and participated in a 1‐h virtual session facilitated using a semi‐structured interview guide. Qualitative data were aggregated, transcribed, and thematically analyzed. Results: The voice analysis examined 11,554 posts from 8321 individuals, discussing MG symptoms, treatments, and burden. Of 7563 symptom‐related posts, 5902 (78%) conveyed negative, 1427 (19%) neutral, and 234 (3%) positive sentiment. The most frequently mentioned symptoms were categorized as dysarthria, muscle weakness, and dysphagia. MG treatment sentiment analysis identified 6667 posts (67%) as neutral, 2887 (29%) as negative, and 350 (4%) as positive. For the focus groups, 15 individuals (12 patients and 3 care partners) completed the questionnaire and 14 participated in the virtual focus group sessions. The 15 participants who completed the questionnaire prioritized treatment convenience, symptom control for improved quality of life, and preventing potential MG crises in their current treatment. New treatment expectations included increased effectiveness, less frequent dosing, faster onset, and fewer side effects. Participants were also receptive to wearable medication delivery systems placed on the body and valued direct involvement in treatment decisions. Conclusion: Patients and care partners are often negatively impacted by MG symptoms and value convenient and fast‐acting treatments that control symptoms with minimal side effects. Considering patient preferences may help optimize treatment decisions and improve patients' overall well‐being and satisfaction in their care. Key points: Recognizing and valuing patients' expertise in their health and treatment preferences is vital, especially since factors such as daily functioning, symptoms, and treatment administration impact patients' daily lives and influence myasthenia gravis (MG) treatment management.Patients and care partners are often negatively impacted by MG symptoms and prioritize convenient treatments that control symptoms with minimal side effects.A greater understanding of these preferences and perspectives may encourage more personalized treatment plans and improved patient experiences in MG. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text